Cargando…

Epigenetic Modulation by Apabetalone Counters Cytokine-Driven Acute Phase Response In Vitro, in Mice and in Patients with Cardiovascular Disease

Chronic systemic inflammation contributes to cardiovascular disease (CVD) and correlates with the abundance of acute phase response (APR) proteins in the liver and plasma. Bromodomain and extraterminal (BET) proteins are epigenetic readers that regulate inflammatory gene transcription. We show that...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wasiak, Sylwia, Gilham, Dean, Daze, Emily, Tsujikawa, Laura M., Halliday, Christopher, Stotz, Stephanie C., Rakai, Brooke D., Fu, Li, Jahagirdar, Ravi, Sweeney, Michael, Johansson, Jan O., Wong, Norman C. W., Kulikowski, Ewelina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7416228/ https://www.ncbi.nlm.nih.gov/pubmed/32821285 http://dx.doi.org/10.1155/2020/9397109

Ejemplares similares

Benefit of Apabetalone on Plasma Proteins in Renal Disease
por: Wasiak, Sylwia, et al.
Publicado: (2017)

Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism
por: Tsujikawa, Laura M., et al.
Publicado: (2019)

Downregulation of the Complement Cascade In Vitro, in Mice and in Patients with Cardiovascular Disease by the BET Protein Inhibitor Apabetalone (RVX-208)
por: Wasiak, Sylwia, et al.
Publicado: (2017)

Inhibition of epigenetic reader proteins by apabetalone counters inflammation in activated innate immune cells from Fabry disease patients receiving enzyme replacement therapy
por: Fu, Li, et al.
Publicado: (2022)

Dual mechanism: Epigenetic inhibitor apabetalone reduces SARS-CoV-2 Delta and Omicron variant spike binding and attenuates SARS-CoV-2 RNA induced inflammation
por: Fu, Li, et al.
Publicado: (2023)

APABETALONE (RVX-208) REDUCES ACE2 PROTEIN ABUNDANCE AND PREVENTS SARS-COV-2 SPIKE PROTEIN BINDING TO HUMAN LUNG CELLS, A MOA THAT COULD ATTENUATE VIRAL ENTRY
por: Fu, Li, et al.
Publicado: (2021)

Apabetalone, a Clinical-Stage, Selective BET Inhibitor, Opposes DUX4 Target Gene Expression in Primary Human FSHD Muscle Cells
por: Sarsons, Christopher D., et al.
Publicado: (2023)

Apabetalone Downregulates Fibrotic, Inflammatory and Calcific Processes in Renal Mesangial Cells and Patients with Renal Impairment
por: Gilham, Dean, et al.
Publicado: (2023)

Data on gene and protein expression changes induced by apabetalone (RVX-208) in ex vivo treated human whole blood and primary hepatocytes
por: Wasiak, Sylwia, et al.
Publicado: (2016)

BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetes
por: Wasiak, Sylwia, et al.
Publicado: (2020)

Bromodomain and Extraterminal Protein Inhibitor, Apabetalone (RVX-208), Reduces ACE2 Expression and Attenuates SARS-Cov-2 Infection In Vitro
por: Gilham, Dean, et al.
Publicado: (2021)

Bromodomain and extraterminal (BET) protein inhibitor, apabetalone, reduces ACE2 expression and attenuates SARS-CoV-2 infection in vitro
por: Gilham, D, et al.
Publicado: (2021)

Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study
por: Nicholls, Stephen J., et al.
Publicado: (2021)

Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled Trial
por: Cummings, Jeffrey, et al.
Publicado: (2021)

Inhibitors of bromodomain and extra‐terminal proteins for treating multiple human diseases
por: Kulikowski, Ewelina, et al.
Publicado: (2020)

Pharmacologic epigenetic modulators of alkaline phosphatase in chronic kidney disease
por: Haarhaus, Mathias, et al.
Publicado: (2020)

Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease
por: Toth, Peter P., et al.
Publicado: (2022)

Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial
por: Schwartz, Gregory G., et al.
Publicado: (2021)

Small Molecule BRD4 Inhibitors Apabetalone and JQ1 Rescues Endothelial Cells Dysfunction, Protects Monolayer Integrity and Reduces Midkine Expression
por: Shahid, Sidra, et al.
Publicado: (2022)

ABCA1 overexpression worsens colorectal cancer prognosis by facilitating tumour growth and caveolin‐1‐dependent invasiveness, and these effects can be ameliorated using the BET inhibitor apabetalone
por: Aguirre‐Portolés, Cristina, et al.
Publicado: (2018)

The Use of Index-Matched Beads in Optical Particle Counters
por: Hu, Zhishang, et al.
Publicado: (2014)

Attention Deficit Hyperactivity Disorder in the Light of the Epigenetic Paradigm
por: Schuch, Viviane, et al.
Publicado: (2015)

A global compact to counter vaccine nationalism
por: Jha, Prabhat, et al.
Publicado: (2021)

Survival of Adult Generated Hippocampal Neurons Is Altered in Circadian Arrhythmic Mice
por: Rakai, Brooke D., et al.
Publicado: (2014)

An introduction to radiation counters and detectors
por: Washtell, C C H
Publicado: (1958)

The velocity-selecting Cerenkov counter
por: Chamberlain, O, et al.
Publicado: (1956)

Counter-ion effect on antistaphylococcal activity and cytotoxicity of selected antimicrobial peptides
por: Sikora, Karol, et al.
Publicado: (2018)

Bax/Bak promote sumoylation of DRP1 and its stable association with mitochondria during apoptotic cell death
por: Wasiak, Sylwia, et al.
Publicado: (2007)

Progress Report on the LGSS Counter
por: Checchia, P, et al.
Publicado: (1983)

In the rich counter
Publicado: (1984)

DISC counters
Publicado: (1971)

double counter
Publicado: (arou)

Scintillation counters
por: Birks, John Bettely
Publicado: (1954)

Cerenkov counters
por: Marshall, J
Publicado: (1956)

Cerenkov counters
por: Hofstadter, R
Publicado: (1956)

Preset counter
por: Daems, G
Publicado: (1967)

Counter-reply
por: Dias, Maria Fernanda Reis Gavazzoni
Publicado: (2015)

Counter Practice
Publicado: (1862)

Counter-Irritation
Publicado: (1882)

Counter Prescribing
Publicado: (1907)

Cannot write session to /tmp/vufind_sessions/sess_496bujalp8q6lu9da178hea2dp